Abstract This article reports a case of incomplete Kawasaki disease with no response to intravenous immunoglobulin (IVIG). A girl, aged 1 year, had the symptoms of fever, rash, finger desquamation, and coronary artery ectasia. She still had fever at 36 hours after the first dose of IVIG treatment, and her temperature returned to normal after the second dose of IVIG treatment. The follow-up after 1 month showed that the coronary artery diameter returned to normal. This article summarizes the experience in the treatment of incomplete Kawasaki disease with no response to IVIG in order to reduce the incidence of coronary artery damage.
YANG Zhao-Yu,LIU Jia-Yi,YAN Xian-Peng et al. Clinical experience in the treatment of incomplete Kawasaki disease with no response to intravenous immunoglobulin: a case report[J]. CJCP, 2022, 24(12): 1311-1312.
YANG Zhao-Yu,LIU Jia-Yi,YAN Xian-Peng et al. Clinical experience in the treatment of incomplete Kawasaki disease with no response to intravenous immunoglobulin: a case report[J]. CJCP, 2022, 24(12): 1311-1312.
McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association[J]. Circulation, 2017, 135(17): e927-e999. PMID: 28356445. DOI: 10.1161/CIR.0000000000000484.
Yang TJ, Lin MT, Lu CY, et al. The prevention of coronary arterial abnormalities in Kawasaki disease: a meta-analysis of the corticosteroid effectiveness[J]. J Microbiol Immunol Infect, 2018, 51(3): 321-331. PMID: 28927685. DOI: 10.1016/j.jmii.2017.08.012.
Tajima M, Shiozawa Y, Kagawa J. Early appearance of principal symptoms of Kawasaki disease is a risk factor for intravenous immunoglobulin resistance[J]. Pediatr Cardiol, 2015, 36(6): 1159-1165. PMID: 25753685. DOI: 10.1007/s00246-015-1136-2.
Lin MC, Lai MS, Jan SL, et al. Epidemiologic features of Kawasaki disease in acute stages in Taiwan, 1997-2010: effect of different case definitions in claims data analysis[J]. J Chin Med Assoc, 2015, 78(2): 121-126. PMID: 25636582. PMCID: PMC7105041. DOI: 10.1016/j.jcma.2014.03.009.
Muta H, Ishii M, Yashiro M, et al. Late intravenous immunoglobulin treatment in patients with Kawasaki disease[J]. Pediatrics, 2012, 129(2): e291-e297. PMID: 22250032. DOI: 10.1542/peds.2011-1704.
Manlhiot C, O'Shea S, Bernknopf B, et al. Epidemiology of Kawasaki disease in Canada 2004 to 2014: comparison of surveillance using administrative data vs periodic medical record review[J]. Can J Cardiol, 2018, 34(3): 303-309. PMID: 29395706. DOI: 10.1016/j.cjca.2017.12.009.
Fukazawa R, Kobayashi J, Ayusawa M, et al. JCS/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease[J]. Circ J, 2020, 84(8): 1348-1407. PMID: 32641591. DOI: 10.1253/circj.CJ-19-1094.
Soni PR, Noval Rivas M, Arditi M. A comprehensive update on Kawasaki disease vasculitis and myocarditis[J]. Curr Rheumatol Rep, 2020, 22(2): 6. PMID: 32020498. DOI: 10.1007/s11926-020-0882-1.
